IOVA Trading Analysis - 10/30/2026 10:08 AM — TRU-SENTIMENT

IOVA (Iovance Biotherapeutics Inc. Common Stock) at $8.48. True Sentiment Bullish, delta 40-60 call 74% / put 26%, call $141,870 vs put $49,495. RSI 26.4.

TRU-SENTIMENT · DeltaNeutral

IOVA Trading Analysis - 10/30/2026 10:08 AM — TRU-SENTIMENT

Options chain · Stock chart · Baseline chart

IOVA (Iovance Biotherapeutics Inc. Common Stock) at $8.48. True Sentiment Bullish, delta 40-60 call 74% / put 26%, call $141,870 vs put $49,495. RSI 26.4.

Symbol
IOVA
Price
$8.48
Article bias (separate from True Sentiment)
neutral
Conviction
low
Published
2026-10-30 10:08:00 ET
Author
DeltaNeutral staff

TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)

True Sentiment Analysis (Delta 40-60 Options)

Options flow (2026-10-30 10:08) shows Bullish:

Call Volume: $141,870 (74.1%) Put Volume: $49,495 (25.9%) Total: $191,365

854 call contracts vs 244 put; 12 call trades vs 10 put. Pure directional conviction leans bullish near-term despite price collapse. Divergence: technicals bearish/oversold, sentiment bullish — matches spread engine note: "Divergence detected between technical indicators and options sentiment."

Key Statistics: IOVA

$8.48 -12.22%
52-Week Range
$1.76 - $15.37
Market Cap
$3.84B
P/E (TTM)
N/A
PEG Ratio
N/A
Beta
1.85
Next Earnings
N/A
Avg Volume
$14.56M
Dividend Yield
0.00%

Fundamental Snapshot

Valuation

EPS (trailing 12 mo)$-0.72
Market cap$3.84B
Shares outstanding453.0M

Dividend

Dividend yield0.00%

Risk & range

Beta1.85
52-week low$1.76
52-week high$15.37
Historical volatility99.6%

Ownership & trading

Institutional ownership35.0%
Average daily volume11.7M sh

Reported figures; no analyst estimates.


📈 Analysis

News Headlines & Context

Iovance Biotherapeutics (IOVA) is a clinical-stage biotech focused on tumor-infiltrating lymphocyte (TIL) therapies. Based on general knowledge, recent context likely includes:

  • FDA review updates or label expansions for Amtagvi (lifileucel) in melanoma and potentially other solid tumors.
  • Q3 2026 earnings approaching, with focus on commercial launch uptake and cash burn.
  • Possible clinical trial readouts from TIL pipeline candidates in cervical or lung cancer.
  • Biotech sector volatility tied to rate expectations and healthcare policy headlines.

Context: A sharp intraday drop on 2026-10-29 (close $9.66 vs prior $14.70) may reflect a catalyst or broad biotech de-risking. Options sentiment is bullish via delta 40-60 flow, suggesting some traders expect a rebound despite weak technicals.

Fundamental Analysis

Based strictly on embedded fundamentals:

  • Trailing EPS: -$0.72 (negative; no profitability).
  • Trailing P/E: null (not applicable due to negative earnings).
  • Forward P/E: null; PEG: null (no valuation multiples available).
  • Market Cap: $3.84B; Shares Out: 452.97M.
  • 52-week range: $1.76 to $15.37 (current $9.66 near lower-mid).
  • Institutional ownership: 35.01% (moderate).
  • Beta: 1.85 (high systematic risk).
  • Historical Volatility: 99.64% (extreme).
  • Dividend Yield: 0.00%; no dividend.
  • Revenue, margins, ROE, D/E, FCF: null (not provided).
  • Analyst target mean: null; recommendations: null.

Fundamentals show a pre-revenue/negative-earnings biotech with high volatility and no valuation anchors. This diverges from technical weakness (RSI 26.45) but aligns with options bullishness as a speculative recovery bet.

Current Market Position

Current price (2026-10-29 close): $9.66. Minute bars show 2026-10-29 opened $10.70, high $11.58, low $9.35, closed $9.66 on 52.16M volume (vs 20d avg 11.23M). 2026-10-30 09:40 bar: open $8.81, high $8.81, low $8.46, close $8.48, vol 1.03M — continued downside.

Key levels from data: 30-day low $9.35, 30-day high $15.37. Daily close support near $9.35; resistance from prior consolidation $13.00–$14.70.

Technical Indicators

RSI (14)
26.45
MACD
0.46 / 0.37 / 0.09
SMA 5
13.32
SMA 20
13.90
SMA 50
11.38
Boll Mid
13.90
Boll Up
16.14
Boll Low
11.65
ATR 14
1.19

Technical Analysis

Price $9.66 is below SMA 5 ($13.32), SMA 20 ($13.90), SMA 50 ($11.38) — bearish alignment, no bullish crossover. RSI 26.45 indicates oversold momentum. MACD (0.46) above signal (0.37), histogram +0.09, mildly bullish divergence vs price drop. Bollinger lower band $11.65; price below band = expansion/oversold. 30-day range $9.35–$15.37; price at 0% of range (near low).

True Sentiment Analysis (Delta 40-60 Options)

Options flow (2026-10-30 10:08) shows Bullish:

Call Volume: $141,870 (74.1%) Put Volume: $49,495 (25.9%) Total: $191,365

854 call contracts vs 244 put; 12 call trades vs 10 put. Pure directional conviction leans bullish near-term despite price collapse. Divergence: technicals bearish/oversold, sentiment bullish — matches spread engine note: "Divergence detected between technical indicators and options sentiment."

Key Price Levels (Observational Only)

Support
$9.35
Resistance
$11.38
Resistance
$13.90
Range Low
$9.35
Range High
$15.37

Interactive charts load with JavaScript. This text is the crawlable summary.